Clinical Trial Update: Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating blinatumomab on minimal residual disease in high-risk diffuse large B-cell lymphoma after autologous stem cell transplantation; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: High-risk Diffuse Large B-cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-09-11